JP7099824B2 - 抗菌化合物 - Google Patents

抗菌化合物 Download PDF

Info

Publication number
JP7099824B2
JP7099824B2 JP2017567655A JP2017567655A JP7099824B2 JP 7099824 B2 JP7099824 B2 JP 7099824B2 JP 2017567655 A JP2017567655 A JP 2017567655A JP 2017567655 A JP2017567655 A JP 2017567655A JP 7099824 B2 JP7099824 B2 JP 7099824B2
Authority
JP
Japan
Prior art keywords
mmol
compound
ring
alkyl
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017567655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524339A5 (enExample
JP2018524339A (ja
Inventor
ギレモン，ジェローム，エミル，ゲオルグ
モッテ，マガリ，マドレーヌ，シモーヌ
ラボワソン，ピエール，ジャン－マリ，ベルナール
タリ，アブデラ
Original Assignee
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56289523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7099824(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー filed Critical ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Publication of JP2018524339A publication Critical patent/JP2018524339A/ja
Publication of JP2018524339A5 publication Critical patent/JP2018524339A5/ja
Priority to JP2021194493A priority Critical patent/JP7516338B2/ja
Application granted granted Critical
Publication of JP7099824B2 publication Critical patent/JP7099824B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2017567655A 2015-07-02 2016-07-01 抗菌化合物 Active JP7099824B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021194493A JP7516338B2 (ja) 2015-07-02 2021-11-30 抗菌化合物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15174936.3 2015-07-02
EP15174936 2015-07-02
EP16174713.4 2016-06-16
EP16174713 2016-06-16
EP16174718.3 2016-06-16
EP16174718 2016-06-16
PCT/EP2016/065499 WO2017001660A1 (en) 2015-07-02 2016-07-01 Antibacterial compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021194493A Division JP7516338B2 (ja) 2015-07-02 2021-11-30 抗菌化合物

Publications (3)

Publication Number Publication Date
JP2018524339A JP2018524339A (ja) 2018-08-30
JP2018524339A5 JP2018524339A5 (enExample) 2019-08-08
JP7099824B2 true JP7099824B2 (ja) 2022-07-12

Family

ID=56289523

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017567655A Active JP7099824B2 (ja) 2015-07-02 2016-07-01 抗菌化合物
JP2017567289A Pending JP2018519302A (ja) 2015-07-02 2016-07-01 抗菌化合物
JP2021194493A Active JP7516338B2 (ja) 2015-07-02 2021-11-30 抗菌化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017567289A Pending JP2018519302A (ja) 2015-07-02 2016-07-01 抗菌化合物
JP2021194493A Active JP7516338B2 (ja) 2015-07-02 2021-11-30 抗菌化合物

Country Status (29)

Country Link
US (6) US20180155341A1 (enExample)
EP (3) EP3316969B1 (enExample)
JP (3) JP7099824B2 (enExample)
KR (2) KR20180022833A (enExample)
CN (3) CN107708809A (enExample)
AU (3) AU2016287477B2 (enExample)
BR (1) BR112017028318B1 (enExample)
CA (1) CA2986331A1 (enExample)
CL (1) CL2017003404A1 (enExample)
CO (1) CO2017013408A2 (enExample)
DK (1) DK3316969T3 (enExample)
EA (2) EA201890201A1 (enExample)
ES (1) ES2914681T3 (enExample)
HK (1) HK1249468A1 (enExample)
HR (1) HRP20220339T1 (enExample)
IL (2) IL256391B (enExample)
LT (1) LT3316969T (enExample)
MA (1) MA42293A (enExample)
MD (1) MD3316969T2 (enExample)
MX (2) MX386598B (enExample)
PE (1) PE20180520A1 (enExample)
PH (2) PH12017502298B1 (enExample)
PL (1) PL3316969T3 (enExample)
RS (1) RS63201B1 (enExample)
SI (1) SI3316969T1 (enExample)
SM (1) SMT202200220T1 (enExample)
UA (1) UA125171C2 (enExample)
WO (2) WO2017001661A1 (enExample)
ZA (1) ZA201708692B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108601B (zh) 2014-08-28 2021-08-20 阿森纽荣股份公司 糖苷酶抑制剂
BR112017028318B1 (pt) * 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
CA3094197C (en) 2015-07-02 2023-02-28 F. Hoffmann-La Roche Ag Bicyclic lactams and methods of use thereof
WO2017049321A1 (en) 2015-09-17 2017-03-23 Miller Marvin J Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection
SG11201807012QA (en) 2016-02-25 2018-09-27 Asceneuron S A Acid addition salts of piperazine derivatives
WO2017144633A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Glycosidase inhibitors
AU2017222964B2 (en) 2016-02-25 2020-01-02 Asceneuron S. A. Glycosidase inhibitors
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
BR112018068703B1 (pt) 2016-03-16 2024-02-06 Kura Oncology, Inc. Inibidores substituídos de menin-mll e métodos de uso
EP3472158A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
AU2018216040A1 (en) * 2017-02-06 2019-06-20 Janssen Pharmaceutica Nv OGA inhibitor compounds
EP3589323B1 (en) 2017-03-01 2024-04-03 Janssen Sciences Ireland Unlimited Company Combination therapy for the treatment of tuberculosis
WO2019037860A1 (en) 2017-08-24 2019-02-28 Asceneuron S.A. LINEAR INHIBITORS OF GLYCOSIDASE
WO2019060365A1 (en) * 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
CA3079188A1 (en) 2017-10-17 2019-04-25 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
US11299481B2 (en) 2017-10-20 2022-04-12 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor M4
EP3732163A4 (en) 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
RU2680972C1 (ru) * 2018-02-13 2019-03-01 Федеральное государственное бюджетное научное учреждение "Центральный научно-исследовательский институт туберкулеза" Способ определения длительности химиотерапии туберкулеза органов дыхания с множественной и широкой лекарственной устойчивостью МБТ у детей и подростков
WO2019175737A1 (en) * 2018-03-12 2019-09-19 University Of Notre Dame Du Lac Deuterated imidazopyridines
CN112074519B (zh) 2018-04-20 2024-08-02 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗例如肠易激综合征(ibs)的化合物
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
MA53429A (fr) 2018-08-22 2022-03-30 Asceneuron Sa Sels d'addition d'acide succinate et fumarate de dérivés de pipérazine utiles en tant qu'inhibiteurs de glycosidase
CN109503631A (zh) * 2018-12-29 2019-03-22 中国医学科学院医药生物技术研究所 含有二氮杂螺环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法和应用
EP3976031A4 (en) * 2019-05-28 2023-07-12 Shionogi & Co., Ltd MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF A MYCOBACTERIAL INFECTION CHARACTERIZED BY THE COMBINATION OF A BC1 INHIBITOR WITH CLARITHROMYCIN OR AZITHROMYCIN AND CLOFAZIMINE
KR102076958B1 (ko) 2019-06-24 2020-02-13 엘티소재주식회사 헤테로고리 화합물 및 이를 이용한 유기 발광 소자
TWI861208B (zh) 2019-09-10 2024-11-11 日商鹽野義製藥股份有限公司 對分枝桿菌感染有用之含苄胺的 5,6-雜芳族化合物
MX2022003037A (es) 2019-09-13 2022-04-07 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
CA3151712A1 (en) 2019-09-30 2021-04-08 Jerome Emile Georges Guillemont Cytochrome bd inhibitors as anti-bacterial agents for the treatment of tuberculosis
AU2020358643A1 (en) 2019-09-30 2022-05-26 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
US12383548B2 (en) 2019-12-27 2025-08-12 Tecnimede—Sociedade Técnico-Medicinal, SA Antibacterial quinolines
CN117396475A (zh) 2021-03-16 2024-01-12 爱尔兰詹森科学公司 抗菌化合物
MX2023010941A (es) * 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
BR112023018655A2 (pt) 2021-03-17 2023-12-12 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
JP2024521618A (ja) * 2021-04-23 2024-06-04 エフ． ホフマン－ラ ロシュ アーゲー 複素環式化合物
WO2023275744A1 (en) 2021-06-29 2023-01-05 TECNIMEDE - Sociedade Técnico-medicinal, SA Heterocyclic compounds for the treatment of tuberculosis
TW202325274A (zh) 2021-10-28 2023-07-01 愛爾蘭商健生科學愛爾蘭無限公司 抗菌化合物
CN114957954B (zh) * 2022-05-16 2024-08-20 万华化学集团股份有限公司 一种用于光学透镜的热塑性树脂组合物及其制备方法和应用
WO2023244764A1 (en) * 2022-06-15 2023-12-21 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds
CN121604963A (zh) 2023-07-18 2026-03-03 詹森药业有限公司 包含贝达喹啉、普托马尼或德拉马尼的至少三种抗生素与细胞色素bc1抑制剂的组合产品及其在治疗分枝杆菌感染中的用途
WO2025129116A1 (en) * 2023-12-14 2025-06-19 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522253A (ja) 2010-03-18 2013-06-13 インスティチュート・パスツール・コリア 抗感染化合物
JP2015508786A (ja) 2012-03-02 2015-03-23 ジェネンテック， インコーポレイテッド アミドスピロ環状アミド及びスルホンアミド誘導体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ295528A (en) 1994-11-15 1999-03-29 Upjohn Co Bicyclic oxazine and thiazine oxazolidinone antibacterials
ES2162047T3 (es) 1995-05-11 2001-12-16 Upjohn Co Oxazolidinonas con resto diazinilo y carbazinilo espirociclico y biciclico.
ES2343458T3 (es) 2002-07-25 2010-08-02 Janssen Pharmaceutica Nv Derivados de quinolina y su uso como inhibidores de micobacterias.
AR042956A1 (es) 2003-01-31 2005-07-13 Vertex Pharma Inhibidores de girasa y usos de los mismos
MA27360A1 (fr) 2004-11-23 2005-06-01 Brahim Bennani Synthese et application des spiro-isoxazolines comme agents anti-tuberculeux
CA2672960A1 (en) 2006-12-20 2008-07-10 Schering Corporation Novel jnk inhibitors
TW200901969A (en) * 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
TWI498115B (zh) 2007-12-27 2015-09-01 Daiichi Sankyo Co Ltd 咪唑羰基化合物
JP5613656B2 (ja) 2008-03-26 2014-10-29 グローバル、アライアンス、フォア、ティービー、ドラッグ、ディベロップメント 置換されたフェニルオキサゾリジノンと共有結合した二環式ニトロイミダゾール
EP2353008A2 (en) 2008-09-22 2011-08-10 Oregon Health and Science University Methods for detecting a mycobacterium tuberculosis infection
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
RU2608611C2 (ru) 2009-11-05 2017-01-23 Юниверсити Оф Нотр Дам Дю Лак СОЕДИНЕНИЯ ИМИДАЗО[1,2-а] ПИРИДИНА, ИХ СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ
KR102104125B1 (ko) 2011-04-21 2020-05-29 재단법인 한국파스퇴르연구소 소염 화합물
AU2012302176A1 (en) 2011-09-01 2014-04-17 Irm Llc Compounds and compositions as c-kit kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
JP6134319B2 (ja) 2011-09-01 2017-05-24 ノバルティス アーゲー ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物
KR101918469B1 (ko) 2012-06-04 2018-11-15 한국화학연구원 바이사이클릭 니트로이미다졸 유도체 또는 이들의 광학이성질체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
WO2014015167A2 (en) * 2012-07-18 2014-01-23 University Of Notre Dame Du Lac 5,5-heteroaromatic anti-infective compounds
KR101650716B1 (ko) 2012-11-22 2016-08-24 한국화학연구원 바이시클릭니트로이미다졸 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 결핵의 예방 또는 치료용 약학적 조성물
CN105745208A (zh) 2013-08-02 2016-07-06 韩国巴斯德研究所 一种抗感染化合物
KR101564425B1 (ko) 2013-11-26 2015-10-30 한국화학연구원 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물
CN105524058B (zh) 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
WO2016073524A1 (en) 2014-11-03 2016-05-12 The Regents Of The University Of California Multi-drug therapies for tuberculosis treatment
BR112017028318B1 (pt) * 2015-07-02 2024-02-20 Janssen Sciences Ireland Uc Composto antibacteriano, seu uso, processo para sua preparação,produto que o contém, composição farmacêutica e combinação
CA3025727A1 (en) 2016-06-16 2017-12-21 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
EP3472158A1 (en) 2016-06-16 2019-04-24 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
EP3589323B1 (en) 2017-03-01 2024-04-03 Janssen Sciences Ireland Unlimited Company Combination therapy for the treatment of tuberculosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522253A (ja) 2010-03-18 2013-06-13 インスティチュート・パスツール・コリア 抗感染化合物
JP2015508786A (ja) 2012-03-02 2015-03-23 ジェネンテック， インコーポレイテッド アミドスピロ環状アミド及びスルホンアミド誘導体

Also Published As

Publication number Publication date
UA125171C2 (uk) 2022-01-26
IL256379A (en) 2018-02-28
EP3316968A1 (en) 2018-05-09
JP7516338B2 (ja) 2024-07-16
MD3316969T2 (ro) 2022-07-31
AU2022200385B2 (en) 2024-06-13
CA2986326A1 (en) 2017-01-05
MX2017016789A (es) 2018-06-11
PH12017502298A1 (en) 2018-06-11
PH12017502297A1 (en) 2018-06-25
US20190330189A1 (en) 2019-10-31
BR112017028318B1 (pt) 2024-02-20
LT3316969T (lt) 2022-03-25
WO2017001661A1 (en) 2017-01-05
SI3316969T1 (sl) 2022-05-31
ZA201708692B (en) 2024-07-31
DK3316969T3 (da) 2022-05-02
JP2018524339A (ja) 2018-08-30
EP4074378A1 (en) 2022-10-19
EP3316969A1 (en) 2018-05-09
JP2018519302A (ja) 2018-07-19
US20180186768A1 (en) 2018-07-05
US20240132470A1 (en) 2024-04-25
US20180155341A1 (en) 2018-06-07
KR20180022833A (ko) 2018-03-06
CN107708809A (zh) 2018-02-16
AU2016287478B2 (en) 2021-10-21
BR112017028318A2 (pt) 2018-09-04
IL256391A (en) 2018-02-28
RS63201B1 (sr) 2022-06-30
ES2914681T3 (es) 2022-06-15
NZ774761A (en) 2024-09-27
CL2017003404A1 (es) 2018-05-11
MX386598B (es) 2025-03-19
KR20180022826A (ko) 2018-03-06
SMT202200220T1 (it) 2022-07-21
PH12017502298B1 (en) 2018-06-11
IL256391B (en) 2021-03-25
CN113980015A (zh) 2022-01-28
US10364232B2 (en) 2019-07-30
PL3316969T3 (pl) 2022-06-20
US11866419B2 (en) 2024-01-09
US20230014173A1 (en) 2023-01-19
PE20180520A1 (es) 2018-03-14
CO2017013408A2 (es) 2018-05-31
EP3316969B1 (en) 2022-03-02
HK1254677A1 (zh) 2019-07-26
CN108235704B (zh) 2021-10-26
CN108235704A (zh) 2018-06-29
AU2016287477A1 (en) 2017-11-30
AU2016287478A1 (en) 2017-11-30
EA201890204A1 (ru) 2018-06-29
NZ737408A (en) 2024-07-26
JP2022043078A (ja) 2022-03-15
CA2986331A1 (en) 2017-01-05
EA201890201A1 (ru) 2018-06-29
HK1249468A1 (zh) 2018-11-02
KR102710552B1 (ko) 2024-09-25
HRP20220339T1 (hr) 2022-05-13
US11180472B2 (en) 2021-11-23
WO2017001660A1 (en) 2017-01-05
AU2022200385A1 (en) 2022-02-17
MA42293A (fr) 2018-05-09
AU2016287477B2 (en) 2021-10-21
US20200239434A1 (en) 2020-07-30
MX2017016788A (es) 2018-07-06

Similar Documents

Publication Publication Date Title
JP7099824B2 (ja) 抗菌化合物
KR20190017948A (ko) 항균제로서의 헤테로고리 화합물
KR20190018681A (ko) 항균제로서의 헤테로고리 화합물
CA2986326C (en) Antibacterial compounds
HK40067537A (en) Antibacterial compounds
HK1254677B (zh) 抗细菌化合物
HK40004907A (zh) 作为抗细菌剂的杂环化合物
HK40004927A (zh) 杂环化合物作为抗细菌剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190628

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190628

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220630

R150 Certificate of patent or registration of utility model

Ref document number: 7099824

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250